Valuation : Alaunos Therapeutics, Inc.

Market Cap 4.19M 3.61M 3.38M 3.1M 5.78M 396M 5.83M 40.04M 15.59M 203M 15.74M 15.4M 652M P/E 2024
-0.65x
P/E 2025 -1.47x
Enterprise Value 2.81M 2.41M 2.27M 2.07M 3.87M 265M 3.9M 26.81M 10.44M 136M 10.54M 10.31M 437M EV / Sales 2024
195,938,500x
EV / Sales 2025 1,164,761,400x
Free-Float
84.7%
Yield 2024 *
-
Yield 2025 -
1 day-1.20%
1 week-0.60%
Current month-2.94%
1 month-13.39%
3 months-37.02%
6 months-50.75%
Current year-48.92%
1 week 1.57
Extreme 1.57
1.73
1 month 1.55
Extreme 1.55
2.05
Current year 1.55
Extreme 1.55
4.04
1 year 1.55
Extreme 1.55
4.59
3 years 1.31
Extreme 1.3137
32.85
5 years 1.31
Extreme 1.3137
601.5
10 years 1.31
Extreme 1.3137
1,182
Manager TitleAgeSince
Chief Executive Officer 63 02/07/2025
Director of Finance/CFO 42 22/02/2025
Director TitleAgeSince
Director/Board Member 56 16/12/2020
Chairman 63 22/09/2023
Director/Board Member 72 05/02/2021
Date Insider Type Main position Quantity % Market Cap. Importance
6/8/26 Free

Chief Executive Officer

4,363 0.1787%
23/7/26 Free

Director

8,138 0.3332%
23/7/26 Free

Chief Executive Officer

4,568 0.1870%
Change 5-day change 1-year change 3-year change Capi.($)
-1.20%-0.60%-26.34%-92.35% 4.19M
+0.41%-2.07%+41.26%+95.40% 69.02B
-0.79%+1.12%+43.36%+90.61% 66.32B
+0.04%+4.36%-11.72%+459.54% 27.66B
-0.90%-7.65%+2.45%-15.50% 25.84B
-3.00%-2.90%+39.40%+9.41% 26.54B
-0.09%+1.90%+25.90%-17.50% 20.4B
+3.45%-13.46%+222.69%+389.50% 17.63B
-1.49%-4.88%-0.41%+530.26% 15.15B
+1.03%+7.00%+59.98%+160.03% 14.65B
Average -0.25%-1.30%+39.66%+160.94% 28.32B
Weighted average by Cap. -0.26%-0.83%+41.79%+148.44%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.95 0.01 0.1 0.04 0.48 0.04 0.04 1.56 0 0 0 0 0.01 0.47 0.01 0.05 0.02 0.24 0.02 0.02 0.78
Net income -4.68M -4.03M -3.78M -3.46M -6.45M -442M -6.5M -44.69M -17.4M -226M -17.57M -17.19M -728M -4.18M -3.59M -3.37M -3.08M -5.76M -395M -5.8M -39.89M -15.53M -202M -15.68M -15.34M -650M
Net Debt -1.09M -939K -881K -806K -1.5M -103M -1.52M -10.42M -4.06M -52.7M -4.1M -4.01M -170M -1.38M -1.19M -1.12M -1.02M -1.91M -131M -1.92M -13.23M -5.15M -66.91M -5.2M -5.09M -215M
Logo Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Employees
1
Date Price Change Volume
03/09/26 US$1.650 -1.20% 2,911
02/09/26 US$1.670 +0.60% 8,501
01/09/26 US$1.660 -2.35% 6,369
31/08/26 US$1.700 +5.92% 13,211
28/08/26 US$1.605 -3.31% 35,678

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRT Stock